Market Place
Sourcing Support
Manufacturing and Marketing Approval for Three Ingredients and Eight Items
15 Feb 2024 //
PRESS RELEASE
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas
28 Aug 2023 //
GLOBENEWSWIRE
Enforcement Report - Week of February 22, 2023
22 Feb 2023 //
FDA
Sandoz signs deal for antifungal from Astellas in buff-up of anti-infectives
25 Jan 2023 //
ENDPTS
USFDA approves Zydus Lifesciences to market generic Micafungin injection
25 Oct 2022 //
ECONOMIC TIMES
Zydus`s Generic Micafungin Sodium Receives Approval in the U.S.
24 Oct 2022 //
FDA
Nanjing`s Generic Micafungin Sodium Receives Approval in the U.S.
28 Sep 2022 //
FDA
Enforcement Report - Week of September 1, 2021
01 Sep 2021 //
FDA
Xellia Pharms Aps`s Generic Micafungin Sodium Receives Approval In US
02 Jun 2021 //
FDA
U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE
08 Jan 2020 //
PR NEWSWIRE
U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE
07 Jan 2020 //
PR NEWSWIRE
U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE
07 Jan 2020 //
PR NEWSWIRE
Fresenius Kabi`s Generic Micafungin Sodium Receives Approval in US
22 May 2019 //
FDA
Mycamine® (micafungin sodium): Astellas Pharma vs. Xellia Pharmaceuticals
24 Nov 2018 //
PATENT LITIGATION
Apotex’s Generic Micafungin Receives Tentative Approval In US
25 Apr 2018 //
FDA
Enforcement Report - Week of February 14, 2018
14 Feb 2018 //
FDA
Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection
19 Sep 2016 //
EDQM
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.